ライフサイエンスコーパス: remission

1 es) followed by periods of partial recovery (remission).

2 because only a fraction of patients achieve remission.

3 , 24, and 36 months) after the date of first remission.

4 e-onset) were defined by timing of onset and remission.

5 imum 2-year treatment duration and remain in remission.

6 state of tolerance associated with drug-free remission.

7 tical processes are "fixed," present even in remission.

8 e 2 characteristics had <1% chance of asthma remission.

9 profiling information and achieved a 5-month remission.

10 option in younger patients with AML in first remission.

11 ompared to patients who experienced clinical remission.

12 o achieved complete clinical and serological remission.

13 cations and 1-year self-reported comorbidity remission.

14 dependent on anti-TNF therapy for sustained remission.

15 aseline was a negative prognostic factor for remission.

16 uld be repeated in order to achieve clinical remission.

17 mic expression as levels normalized upon EoE remission.

18 ue TKI treatment and maintain a therapy-free remission.

19 ei, thereby bringing about long-term disease remission.

20 reated with mepolizumab had protocol-defined remission.

21 baseline samples from CD patients achieving remission.

22 ures had similarly low efficacy for diabetes remission.

23 Secondary efficacy measures included remission.

24 apse compared with specimens acquired during remission.

25 assification were eligible for ASCT in first remission.

26 s (81.8%) were responders, with 6 of them in remission.

27 lpha, which was highly effective in inducing remission.

28 on may be associated with prolonged ART-free remission.

29 bout 50% show partial, rather than complete, remission.

30 ncreased or decreased from active disease to remission.

31 ly available antidepressants (ADs) show full remission.

32 vided highest classifying power for clinical remission.

33 T123 or CART123-CD20 did not impair leukemia remission.

34 f 19 complete remissions and 3 of 19 partial remissions.

35 with 55% complete remissions and 18% partial remissions.

36 5% CI -10.27 to -4.86]; p<0.0001) and higher remission (147 [64%] of 230 had a PHQ-9 score of <10 in

37 rabine and an increased death probability in remission (15% +/- 2 vs 22% +/- 3).

38 lifetime was low for patients in continuous remission 2 years after ending treatment.

39 .09-8.56; p=0.034), and not achieving week 4 remission (30.28, 6.36-144.20; p<0.0001).

40 on of patients given Cx601 achieved combined remission (56.3%) vs controls (38.6%) (a difference of 1

41 The proportion with remission (59 [36%] of 164 in the EUC plus CAP group vs

42 ts; 95% CI 4.2-31.2; P = .010), and clinical remission (59.2% vs 41.6% of controls, for a difference

43 s a significantly higher rate of sleep apnea remission (72.5% vs 49.3%, P < .001) and higher satisfac

44 ts with FMF isolated both during attacks and remission, 8 patients in remission, and 8 healthy subjec

45 febrile seizures, number of seizures before remission, absence of a self-limiting epilepsy syndrome,

46 a 99% chance of CAP being cost-effective per remission achieved from a health system perspective, usi

47 -7.26, -1.63; p = 0.002) and higher rates of remission (adjusted prevalence ratio [aPR] = 1.36; 95% C

48 d that patients with MDD who did not achieve remission after 12 mo of naturalistic treatment had lowe

49 months (OR, 6.125; 95% CI, 1.330-28.22), and remission after 12 months (OR, 5.333; 95% CI, 1.132-25.1

50 Twelve women who experienced symptom remission after 2-3 months of GnRH agonist-induced ovari

51 proven idiopathic/primary MGN who achieved a remission after a period of nephrotic-range proteinuria.

52 etastatic melanoma can have durable complete remission after discontinuation of pembrolizumab, and th

53 In conclusion, T2D remission after DS is mainly associated with greater cir

54 emcomitans Ltx are associated with decreased remission after otherwise successful periodontal treatme

55 ities for use as predictive markers for T2DM remission after Roux-en-Y gastric bypass (RYGB).

56 ciated with greater possibility for diabetes remission after RYGB [odds ratio, 2.16 (95% CI 1.10-4.26

57 ociated with greater probability of diabetes remission after RYGB and may serve as a diagnostic marke

58 other measures, as a potential biomarker for remission after standardized escitalopram treatment.

59 overall classification rates of 72%-78% for remission and 75%-89% for treatment failure was demonstr

60 umab resulted in significantly more weeks in remission and a higher proportion of participants in rem

61 ntion delivered by lay counsellors, enhanced remission and abstinence over 3 months among male primar

62 romoter may predict the likelihood of stable remission and explain autoantigen gene regulation.

63 e achieved complete clinical and serological remission and has remained symptom-free up to 18 months

64 rnational cohort to analyse the frequency of remission and identify preoperative determinants of succ

65 notherapy, which will in turn translate into remission and long-term survival in this patient populat

66 termediate- or unfavorable-risk AML in first remission and no identified donor for allogeneic stem-ce

67 During disease remission and off treatment, sJIA patients displayed dys

68 As alone have not been able to achieve HIV-1 remission and prevent viral rebound following analytical

69 ary, and is focused on the safe induction of remission and prevention of relapse.

70 term durability of weight loss and effective remission and prevention of type 2 diabetes, hypertensio

71 e were unable to assess possible episodes of remission and relapse that may have occurred between our

72 is necessary to determine the durability of remission and safety of tocilizumab.

73 as lower in the Rtx group, rates of complete remission and the composite renal end point did not diff

74 s differentially associated with outcomes of remission and treatment failure to CBT and antidepressan

75 at differentially identifies the outcomes of remission and treatment failure to these interventions.

76 We used logistic regression analysis for remission and zero-inflated negative binomial regression

77 l responses toward testing for sustained HIV remission and/or cure.

78 all remission rate was 73% with 55% complete remissions and 18% partial remissions.

79 Overall, we observed 9 of 19 complete remissions and 3 of 19 partial remissions.

80 Most patients achieve long-lasting remissions and have excellent overall survival (OS) with

81 mes in 19 RRMS patients (9 in relapse, 10 in remission) and 10 HC.

82 rt of 63 RRMS patients (33 in relapse, 30 in remission) and 32 HC.

83 during attacks and remission, 8 patients in remission, and 8 healthy subjects.

84 lead to clonal expansion during hematologic remission, and eventually lead to relapsed disease.

85 2% in children with IIS resistance, complete remission, and partial remission, respectively; 27% in c

86 of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cells.

87 ificantly improved primary anxiety symptoms, remission, and response.

88 he study, those who had frequent relapse and remission, and those who had relentless seizures.

89 of markers of disease relapse and sustained remission are critical next steps in the development of

90 Neutrophils from patients with FMF during remission are resistant to autophagy-mediated NET releas

91 in advanced cutaneous melanoma, but complete remissions are frustrated by the development of acquired

92 Eleven of 12 complete remissions are ongoing.

93 Persistent remission associated with unadjusted hazard ratios for t

94 s analysis was 3-month steroid-free clinical remission at 1 year after HSCT (Crohn's Disease Activity

95 In the OCTAVE Sustain trial, remission at 52 weeks occurred in 34.3% of the patients

96 The primary end point was remission at 52 weeks.

97 In the OCTAVE Induction 1 trial, remission at 8 weeks occurred in 18.5% of the patients i

98 The primary end point was remission at 8 weeks.

99 ation, and the proportion of participants in remission at both week 36 and week 48.

100 All others were alive and in remission at last follow-up (median, 14.7 months).

101 control group, met conventional criteria for remission at study end, resulting in a number needed to

102 as the rate of sustained glucocorticoid-free remission at week 52 in each tocilizumab group as compar

103 Sustained remission at week 52 occurred in 56% of the patients tre

104 12-month follow-up, with the proportion with remission (AUDIT score < 8: 54.3% versus 31.9%; adjusted

105 Primary outcomes were remission (AUDIT score of <8) and mean daily alcohol con

106 itors (TKIs) is highly effective in inducing remission but not in targeting leukemia stem cells (LSCs

107 lating agents can induce sustained drug-free remissions but likely increase the lifetime risk of canc

108 AS(V12) expression results in rapid leukemia remission, but some mice undergo spontaneous relapse wit

109 of disease in cases deemed to be in complete remission by conventional pathologic analysis.

110 eeks) of patients receiving GED-0301 were in remission (CD activity index score <150); corresponding

111 The primary outcome was clinical remission (CDAI <150) at week 12 (intention-to-treat pop

112 , and melphalan group had stringent complete remission compared with 22 of 174 patients (12.6%, 10.1-

113 luate the survival of patients with DLBCL in remission compared with a matched general population.

114 .30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant.

115 s and led to lower remission rates (complete remission + complete remission with incomplete recovery)

116 patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with

117 Seq to compare the RR group and the complete remission (CR) group (a total of 42 adult AML patients).

118 Results Achievement of complete remission (CR) in the absence of MRD negativity was not

119 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arms, respec

120 The primary end point was complete remission (CR) or CR with partial hematologic recovery (

121 Complete remission (CR) with persistence of mIDH2 and normalizati

122 mia (AML) frequently relapses after complete remission (CR), necessitating improved detection and phe

123 We defined complete remission (CR), partial remission (PR), and relapse as p

124 w-up of treatment, and management of relapse/remission cycles in multiple sclerosis patients by provi

125 is analysis were week 12 corticosteroid-free remission, defined as PUCAI less than 10 and taking only

126 ll arms across cytogenetic subgroups, as was remission duration and overall survival.

127 tudy examined the prognostic significance of remission duration in 376 patients with biopsy-proven id

128 Median remission duration was 6 months.

129 , the greater the improvement, patients with remission durations as short as 3 months had improved re

130 nt but only modestly increased likelihood of remission during 12 weeks of treatment compared with swi

131 The primary outcome was remission during the acute treatment phase (16-item Quic

132 Patients with rheumatoid arthritis in remission exhibited high numbers of IL-9(+) ILC2s in joi

133 eukemia characterized by a high incidence of remission failure or hematological relapse after convent

134 story of epilepsy, number of seizures before remission, focal seizures, and epileptiform abnormality

135 yosarcoma and has experienced complete tumor remission for >2 years on anti-PD-1 (pembrolizumab) mono

136 Complete migraine remission for 1 year occurred in 10 patients (8.5%) in t

137 iteria for BPD (cBPD) (n = 23), a patient in remission for 2 years or more (rBPD) (n = 17), or a seco

138 gent primary endpoint (steroid-free clinical remission for 3 months with no endoscopic or radiologica

139 st for future use may be considered in first remission for patients 70 years or younger who are poten

140 ation of prefrontal cortical activity drives remission from ADHD, while anomalies in subcortical proc

141 the Beck Depression Inventory version II and remission from depression (PHQ-9 score of <10) at 3 mont

142 HIV-1 reservoir and a >9-month-long ART-free remission from HIV-1 replication.

143 icantly higher than those in NC group and HB remission group but not statistically different from tho

144 om a case-control study and decreased in the remission group of obese subjects with T2DM after metabo

145 el of 98/muL and those who did not achieve a remission had a median peak blood CAR(+) cell level of 1

146 Patients who achieved a remission had a median peak blood CAR(+) cell level of 9

147 ilepsy nor the patterns of seizure onset and remission have been described in Rett syndrome and relat

148 follow-up of 7 years (range 5-12), diabetes remission (HbA1C <6.5% off medications) was observed in

149 n HRSD-24 score of >/=50% from baseline) and remission (HRSD-24 score </=8), as well as self-assessed

150 A TFGED diet achieves EoE remission in 43% of children and adults.

151 t week 24, was previously reported (combined remission in 51.5% of patients given Cx601 vs 35.6% of c

152 nd melphalan who achieved stringent complete remission in accordance with the International Myeloma W

153 were then validated using the Predictors of Remission in Depression to Individual and Combined Treat

154 robiome towards a healthy state and maintain remission in IBD.

155 effective than placebo for inducing clinical remission in patients with active Crohn's disease.

156 with regard to sustained glucocorticoid-free remission in patients with giant-cell arteritis.

157 on, and better than placebo for induction of remission in patients with moderate to severe ulcerative

158 Surgical treatment can bring seizure remission in people with focal epilepsy but requires car

159 ion of NPM-ALK induces long-lasting complete remissions in a large subset of heavily pretreated adult

160 correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-posi

161 nib produces high response rates and durable remissions in Waldenstrom macroglobulinemia (WM) that ar

162 stent MDD effects across current episodes or remission, in the absence of detectable progressive neur

163 Four independent predictors of long-term remission including preoperative duration of T2DM (P < 0

164 il volume was positively related to clinical remission, independent of total hippocampal volume, tota

165 aematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a favourable

166 res are uncommon in Rett syndrome, prolonged remission is less common than in other causes of childho

167 tors at randomisation were duration of first remission (<12 months vs >/=12 months), salvage treatmen

168 ssion has a low rate of sustained, drug-free remissions, <10%/year.

169 y symptoms more than fluoxetine and improved remission more than sertraline.

170 nce of one or more of epilepsy (active or in remission), motor disability, intellectual disability, o

171 Positive effect of rituximab on proteinuria remission occurred after 6 months.

172 Full clinical remission occurred in 11 (20%) patients receiving cortic

173 (P=0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (P<0.001).

174 Complete remission occurred in 6 of 14 patients with diffuse larg

175 Remission occurs only in a minority of individuals after

176 6 (T-182C) was significantly associated with remission (odds ratio=1.66, 95% CI=1.13, 2.42).

177 ls preceded by low-dose chemotherapy induced remission of advanced-stage lymphoma, and high serum IL-

178 hown to be safe and effective in influencing remission of aggressive lymphomas in HCV patients.

179 ilience shown by some adoptees and the adult remission of cognitive impairment, extended early depriv

180 n analogue, led to dramatic and long-lasting remission of depression.

181 comes were weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin (

182 Remission of hypertension was present in 25 of 49 (51%)

183 ed mucocutaneous candidiasis, and maintained remission of immune-mediated cytopenias.

184 Secondary outcomes were clinician-assessed remission of insomnia; sleep quality; total sleep time,

185 Complete and partial remission of proteinuria within 12 months of disease ons

186 Bariatric surgery may induce remission of psoriasis, but data are limited to small st

187 Remission of sensitization was uncommon.

188 lted in a full and more than 6 years lasting remission of the disease.

189 s or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of

190 rrence after surgery, facilitating long-term remission of this lethal disease.Significance: Coordinat

191 Remission of type 2 diabetes is a practical target for p

192 Remission of vasculitis has been associated with viral c

193 Complete remission off anti-seizure medications is possible, but

194 he Beck Depression Inventory-II (BDI-II) and remission on the PHQ-9.

195 karos is restored, causing sustained disease remission or ablation.

196 apy (ART) may lead to long-term ART-free HIV remission or cure.

197 atients who would attain complete or partial remission or no-response to first-line chemotherapy.

198 Patients in complete remission or partial remission received six reinduction

199 Complete remission or partial remission was achieved in 247 patie

200 nd it is still obscure which factors predict remission or persistence of the disease.

201 he survival endpoint could be death, disease remission or the occurrence of an adverse drug reaction.

202 ly identified an individual's probability of remission or treatment failure with first-line treatment

203 Chronic illnesses may deteriorate, enter remission, or fluctuate, but their defining characterist

204 ing complete stable remission, pharmacologic remission, or minimal manifestations based on the Myasth

205 th therapy intensity, likelihood of complete remission, or survival (high income: adjusted HR, 1.0; m

206 n a cohort of 416 children with ALL in first remission over 4 study months (1344 patient-months for t

207 primary end points were the accrued weeks of remission over a 52-week period, according to categorica

208 he 34 patients (19.3%) who attained complete remission, overall survival was 19.7 months.

209 to 34.0) patients in the NIAT group achieved remission (P=0.21).

210 ghly expressed in non-responders and partial remission patients than in complete remission patients.

211 partial remission patients than in complete remission patients.

212 Once in complete remission, patients received 4 cycles of ATRA plus ATO c

213 y, reduced therapeutic response, and shorter remission periods, suggesting the presence of a persiste

214 with all patients achieving complete stable remission, pharmacologic remission, or minimal manifesta

215 We defined complete remission (CR), partial remission (PR), and relapse as proteinuria </=0.3, 0.4-3

216 se, achieving accuracy of 89, 90 and 86% for remission prediction in three independent, age-matched d

217 rst treatment, we examined the durability of remission, progression-free survival (PFS), overall surv

218 ite light experienced a significantly higher remission rate (68.2% compared with 22.2%; adjusted odds

219 pared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% c

220 e mutations associated with a lower complete remission rate (P = 0.03).

221 t minimal residual disease-negative (MRD(-)) remission rate for this phase 1 study was 89%.

222 The remission rate is believed to be low, and it is still ob

223 Results The overall remission rate was 73% with 55% complete remissions and

224 The complete remission rate was 96% (52 of 54 in high-risk and 127 of

225 Complete remission rates (89%) did not differ but were attained f

226 non-CBF aberrant karyotypes and led to lower remission rates (complete remission + complete remission

227 of children, respectively, with the highest remission rates achieved with calcineurin inhibitor-base

228 The surgery group had higher remission rates and lower incidence rates of hypertensio

229 id leukemia (AML) have been shown to improve remission rates and survival.

230 Remission rates at week 12 were significantly greater in

231 During the observational phase, remission rates before change of assigned treatment were

232 Last observation carried forward remission rates did not significantly differ between tre

233 ies continue to focus on increasing complete remission rates that allow more transplant-eligible pati

234 Remission rates were similar for the two groups (intent-

235 Remission rates with FFGEDs and SFGEDs were 60% and 79%,

236 Remission rates within 12 weeks after treatment initiati

237 s for the G allele of rs28365143 had greater remission rates, response rates, and symptom reductions.

238 Patients in complete remission or partial remission received six reinduction courses, alternating

239 l models accurately predicted likelihoods of remission, relapse and mortality, which were validated u

240 in multiple sclerosis, where it reflects the remission/relapse alternation.

241 piprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60];

242 duced primary anxiety symptoms and increased remission (relative risk, 2.04; 95% CI, 1.37-3.04) and r

243 e studies demonstrated that durable leukemia remission required CAR T-cell persistence for 4 weeks pr

244 resistance, complete remission, and partial remission, respectively; 27% in children with a genetic

245 s (measured by child, parent, or clinician), remission, response, and adverse events.

246 ) gene predicted antidepressant outcomes for remission, response, and symptom change.

247 r of follow-up were epilepsy duration before remission, seizure-free interval before antiepileptic dr

248 ure recurrence were epilepsy duration before remission, seizure-free interval before antiepileptic dr

249 .70-1.21]), with 56.6% (69 of 122) achieving remission status and 69.7% (85 of 122) deemed treatment

250 hazards models to examine the association of remission status at each landmark and the primary end po

251 The exposure variable was the remission status of patients at fixed landmarks (3, 6, 1

252 edict post-ECT depressive rating changes and remission status using pre-ECT gray matter (GM) in 38 MD

253 ng could improve prediction of posttreatment remission status.

254 a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with incomplete p

255 n and a higher proportion of participants in remission than did placebo, thus allowing for reduced gl

256 the C/C genotype also had a shorter time to remission than those with the C/T or T/T genotypes and h

257 Although the longer the remission, the greater the improvement, patients with re

258 l-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M

259 For patients who achieve clinical remission, there is often interest in discontinuation of

260 However, although successful in inducing remissions, these are normally short-lived, with median

261 atric surgery promotes type 2 diabetes (T2D) remission through a succession of weight loss-dependent

262 antibody levels strongly predict spontaneous remission, thus favoring conservative therapy.

263 months, almost half of participants achieved remission to a non-diabetic state and off antidiabetic d

264 nd (i) a diagnosis of MDD, and (ii) clinical remission to anti-depressant medications (ADMs).

265 plied to 122 patients from the Prediction of Remission to Individual and Combined Treatments (PReDICT

266 nal connectivity scores were associated with remission to medication and treatment failure with CBT.

267 Complete remission (tumor-free fraction, 100%) was found for tumo

268 with sarcoidosis spontaneously achieve full remission (uncomplicated sarcoidosis), however, 20% of

269 and 41 patients in 600 mg arms) had clinical remission versus six (15%) of 39 placebo patients (diffe

270 ant differences between patients with IBD in remission vs controls (P = .261).

271 The incremental cost per additional remission was $217 (95% CI 50-1073), with an 85% chance

272 For secondary outcomes, insomnia remission was 46.2% and 37.9% in CBT-I and TCC, respecti

273 However, complete remission was achieved first at activity levels close to

274 Complete remission or partial remission was achieved in 247 patients (76%).

275 Diabetes remission was achieved in 68 (46%) participants in the i

276 Clinical remission was associated with autoantibody depletion and

277 The incidence of death during remission was comparable, which indicates equivalent tox

278 Remission was defined as an HRSD17 of 7 following 8 week

279 Remission was defined as having a SIGH-ADS score of 8 or

280 Remission was defined by symptom improvement and less th

281 The intervention effect for remission was higher at 12 months than at 3 months (aPR

282 Although the cumulative incidence of partial remission was lower in the Rtx group, rates of complete

283 ar after HSCT, 3-month steroid-free clinical remission was seen in 13 (38%, 95% CI 22-55) of 34 patie

284 Remission was the secondary outcome.

285 Response and remission were defined using the Hamilton Depression Rat

286 High rates of durable remission were observed, with recovery of B cells and im

287 Sustained remissions were achieved, and at a median follow-up of 2

288 functional connectivity was associated with remission with CBT and treatment failure with medication

289 86% of evaluable patients achieved complete remission with DA-TEDDi-R.

290 therapy group, both with respect to complete remission with full hematologic recovery (34% vs. 16%, P

291 . 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hematologic

292 omplete platelet recovery, 46 (18%) complete remission with incomplete haematological recovery, and 2

293 ieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46 (18%) co

294 mission rates (complete remission + complete remission with incomplete recovery), inferior event-free

295 with major depressive disorder (MDD) achieve remission with their first antidepressant.

296 as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major de

297 l of these diseases (clinical and endoscopic remission), with the final aim of blocking their progres

298 ent strategies aim for deep and long-lasting remission, with the goal of preventing complications, su

299 sive disorder are associated with diagnostic remission within 28 weeks in 65-70% of patients.

300 patients with adult-onset asthma experiences remission within the first 5 years of the disease.